Related Experiment Video
Updated: Jul 3, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery
J A Vita1, A C Yeung, M Winniford
1Boston University School of Medicine, Boston, MA, USA. jvita@bu.edu
Insights
Six months of simvastatin treatment did not significantly improve coronary endothelial vasomotor function in patients with coronary artery disease and mildly elevated cholesterol. Cholesterol-lowering therapy
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Endothelial dysfunction is implicated in cardiovascular disease.
- Cholesterol-lowering therapies are known to have cardiovascular benefits.
Purpose of the Study:
- To investigate the effect of simvastatin on coronary endothelial vasomotor function.
- To determine if simvastatin improves endothelial function in patients with coronary artery disease.
Main Methods:
- Randomized, double-blind, placebo-controlled study.
- 60 patients with coronary artery disease received either simvastatin (40 mg/d) or placebo for 6 months.
- Coronary endothelial vasomotor function was assessed using intracoronary infusions of acetylcholine and substance P.
Main Results:
- Simvastatin significantly reduced LDL-cholesterol by 40%.
- Neither simvastatin nor placebo significantly altered epicardial coronary artery constriction in response to acetylcholine.
- Endothelium-dependent dilation of coronary microvessels, assessed by substance P infusion, showed no significant difference between groups after treatment.
Conclusions:
- Six months of simvastatin therapy did not significantly improve coronary endothelial vasomotor function in patients with coronary artery disease and mildly elevated cholesterol.
- The findings suggest that the impact of cholesterol-lowering on endothelial function is complex and may not be solely mediated by direct vasomotor improvements.
- Further research is needed to elucidate the mechanisms underlying the cardiovascular benefits of statin therapy.
Background:
Improved endothelial function may contribute to the beneficial effects of cholesterol-lowering therapy.
Methods And Results:
In this randomized, double-blind study, we compared the effect of 6 months of simvastatin (40 mg/d) treatment with that of placebo on coronary endothelial vasomotor function in 60 patients with coronary artery disease. Simvastatin lowered LDL-cholesterol by 40+/-12% from 130+/-28 mg/dL (P<0.001). Peak intracoronary acetylcholine infusion produced epicardial coronary constriction at baseline in both the simvastatin (-17+/-13%) and placebo (-24+/-16%) groups. After treatment, acetylcholine produced less constriction in both groups (-12+/-19% and -15+/-14%, respectively, P=0.97). The increase in coronary blood flow during infusion of the peak dose of substance P was blunted at baseline in both the simvastatin (42+/-50%) and placebo (55+/-71%) groups, reflecting impaired endothelium-dependent dilation of coronary microvessels. After treatment, the flow increase was 82+/-81% in the simvastatin group and 63+/-53% in the placebo group (P=0.16).
Conclusions:
Six months of cholesterol-lowering therapy has no significant effect on coronary endothelial vasomotor function in the study population of patients with coronary artery disease and mildly elevated cholesterol levels. These findings suggest that the effects of cholesterol lowering on endothelial function are more complex than previously thought.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management

